FRANKLIN BIO
Live / Applied — Response to non-final action entered (as of 20 Oct 2025)
What this means for you
Not registered yet, but its 10 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99035155
- Mark type
- Stylized text
- Filed
- 10 Feb 2025
- Attorney of record
- Victoria D Summerfield
Goods and services
- Class 040 — Treatment of materials: Custom manufacturing services for others in the fields of viral-based and non-viral vectors, pharmaceuticals, biologics, vaccines, biotechnological medical products, and gene and cell therapy preparations
- Class 042 — Scientific and technological services: Pharmaceutical research services; Pharmaceutical drug development and discovery services, namely, providing translational research tools and services, namely, providing scientific research in the field of screening, testing, sequencing, and analysis of DNA- and RNA-encoded genetic material for drug candidate development; cell and gene therapy product development services; Analytical services being scientific research services in the field of drug substance and drug product characterization which are for research use and in accordance with Good Manufacturing Practices (GMP); Preclinical services including pharmacology, pharmacokinetics, and toxicology in well established lab animal models; Scientific research and development and Good Laboratory Practices (GLP) services for bioanalytical testing including immunogenicity, biodistribution and shedding to support pre-clinical (animal) and clinical (human) studies; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing for quality control purposes and analytical scientific advisory services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Good Manufacturing Practices (GMP) laboratory and stability testing for quality control purposes and analytical scientific advisory services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Providing laboratory research services for others in accordance with the Clinical Laboratory Improvement Amendments (CLIA) program to support the development of gene and cell therapy, biologics, vaccines, pharmaceuticals, and related biotechnological products; Research and development relating to production and analysis of viral-based vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations for use in medical research for others
Owner
- Franklin Biolabs, Inc., King of Prussia, PA, US
Prosecution history
- 20 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 07 Oct 2025 — ATTORNEY REVIEW COMPLETED
- 21 Jul 2025 — PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
- 21 Jul 2025 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 21 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 21 Jul 2025 — NON-FINAL ACTION E-MAILED
- 21 Jul 2025 — NON-FINAL ACTION WRITTEN
- 18 Jul 2025 — ASSIGNED TO EXAMINER
- 13 Feb 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Feb 2025 — APPLICATION FILING RECEIPT MAILED
- 10 Feb 2025 — NEW APPLICATION ENTERED